Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas

被引:23
作者
Gow, Chien-Hung [1 ,2 ,3 ]
Hsieh, Min-Shu [4 ]
Lin, Yen-Ting [2 ,5 ]
Liu, Yi-Nan [2 ]
Shih, Jin-Yuan [2 ,5 ,6 ]
机构
[1] Far Eastern Mem Hosp, Dept Internal Med, New Taipei 22060, Taiwan
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei 10002, Taiwan
[3] Ming Chuan Univ, Dept Healthcare Informat & Management, Taoyuan 33348, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10002, Taiwan
[5] Natl Taiwan Univ, Grad Inst Clin Med, Taipei 10002, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 10002, Taiwan
来源
CANCERS | 2019年 / 11卷 / 06期
关键词
BRAF; immunohistochemistry; lung adenocarcinoma; overall survival; pemetrexed; MUTATION-SPECIFIC ANTIBODY; V600E MUTATION; CLINICAL CHARACTERISTICS; DRIVER MUTATIONS; CANCER; FEATURES; OUTCOMES; PROTEIN; CHEMOTHERAPY; DABRAFENIB;
D O I
10.3390/cancers11060866
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRAF V600E mutation, a missense mutation in exon 15 resulting in valine substitution for glutamate at position 600 within the kinase domain of BRAF oncogene, is found in a subset of lung adenocarcinoma (ADC). The usefulness of immunohistochemistry (IHC) as an alternative diagnostic tool has not been validated. Moreover, the clinical information of patients with BRAF V600E-mutated lung ADC is limited. We retrospectively identified 31 lung ADCs diagnosed with BRAF V600E mutation by standard molecular sequencing methods and reviewed their clinical characteristics and pathological features. An anti-BRAF V600E monoclonal VE1 antibody for IHC was used to confirm the expression patterns. The series was comprised of 99 cases, 29 with BRAF V600E mutation and 70 without BRAF V600E but with other types or undetected mutations. The majority of BRAF V600E-mutated biopsied tissues were poorly differentiated and micropapillary patterns. Application of the IHC VE1 assay was highly feasible in primary/metastatic sites or effusion blocks, yielding positive findings in 28 of 29 (96.6%) BRAF V600E-mutated tumors and negative results in 69 of 70 (98.6%) tumors harboring other types or undetected mutations. Patients who received pemetrexed/platinum-based rather than mutation-targeted chemotherapy as the first-line therapy for metastatic disease showed median overall survival of 15.5 months. Our findings indicated that VE1 antibody-based IHC analysis demonstrated high sensitivity and specificity to detect BRAF V600E-mutated lung ADCs in tissues from primary or metastatic sites.
引用
收藏
页数:15
相关论文
共 45 条
  • [21] Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma
    Koperek, Oskar
    Kornauth, Christoph
    Capper, David
    Berghoff, Anna Sophie
    Asari, Reza
    Niederle, Bruno
    von Deimling, Andreas
    Birner, Peter
    Preusser, Matthias
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (06) : 844 - 850
  • [22] Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
    Kris, Mark G.
    Johnson, Bruce E.
    Berry, Lynne D.
    Kwiatkowski, David J.
    Iafrate, A. John
    Wistuba, Ignacio I.
    Varella-Garcia, Marileila
    Franklin, Wilbur A.
    Aronson, Samuel L.
    Su, Pei-Fang
    Shyr, Yu
    Camidge, D. Ross
    Sequist, Lecia V.
    Glisson, Bonnie S.
    Khuri, Fadlo R.
    Garon, Edward B.
    Pao, William
    Rudin, Charles
    Schiller, Joan
    Haura, Eric B.
    Socinski, Mark
    Shirai, Keisuke
    Chen, Heidi
    Giaccone, Giuseppe
    Ladanyi, Marc
    Kugler, Kelly
    Minna, John D.
    Bunn, Paul A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (19): : 1998 - 2006
  • [23] BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
    Leonetti, Alessandro
    Facchinetti, Francesco
    Rossi, Giulio
    Minari, Roberta
    Conti, Antonia
    Friboulet, Luc
    Tiseo, Marcello
    Planchard, David
    [J]. CANCER TREATMENT REVIEWS, 2018, 66 : 82 - 94
  • [24] Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
    Litvak, Anya M.
    Paik, Paul K.
    Woo, Kaitlin M.
    Sima, Camelia S.
    Hellmann, Matthew D.
    Arcila, Maria E.
    Ladanyi, Marc
    Rudin, Charles M.
    Kris, Mark G.
    Riely, Gregory J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1669 - 1674
  • [25] Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
    Long, Georgina V.
    Wilmott, James S.
    Capper, David
    Preusser, Matthias
    Zhang, Yuxiao E.
    Thompson, John F.
    Kefford, Richard F.
    von Deimling, Andreas
    Scolyer, Richard A.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (01) : 61 - 65
  • [26] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ
    Bell, DW
    Sordella, R
    Gurubhagavatula, S
    Okimoto, RA
    Brannigan, BW
    Harris, PL
    Haserlat, SM
    Supko, JG
    Haluska, FG
    Louis, DN
    Christiani, DC
    Settleman, J
    Haber, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139
  • [27] Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations
    Marchetti, Antonio
    Felicioni, Lara
    Malatesta, Sara
    Sciarrotta, Maria Grazia
    Guetti, Luigi
    Chella, Antonio
    Viola, Patrizia
    Pullara, Carmela
    Mucilli, Felice
    Buttitta, Fiamma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3574 - 3579
  • [28] Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
    Mason, CS
    Springer, CJ
    Cooper, RG
    Superti-Furga, G
    Marshall, CJ
    Marais, R
    [J]. EMBO JOURNAL, 1999, 18 (08) : 2137 - 2148
  • [29] Investigation of patterns of nodal metastases in BRAF mutant lung cancer
    McEvoy, S. H.
    Halpenny, D. P.
    Viteri-Jusue, A.
    Hayes, S. A.
    Plodkowski, A. J.
    Riely, G. J.
    Ginsberg, M. S.
    [J]. LUNG CANCER, 2017, 108 : 62 - 65
  • [30] Favorable Outcome With Pemetrexed Treatment for Advanced BRAF-V600E-Positive Lung Adenocarcinoma in a Patient Followed up Over 8 Years
    Nakanishi, Yoko
    Nakagawa, Yoshiko
    Tsujino, Ichiro
    Shimizu, Tetsuo
    Takahashi, Noriaki
    Hashimoto, Shu
    Masuda, Shinobu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : E199 - E202